Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The price of Legend Biotech Corp ADR (NASDAQ: LEGN) closed at $33.72 in the last session, up 1.47% from day before closing price of $33.23. In other words, the price has increased by $1.47 from its previous closing price. On the day, 1.84 million shares were traded. LEGN stock price reached its highest trading level at $34.79 during the session, while it also had its lowest trading level at $33.41.
Ratios:
We take a closer look at LEGN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.57 and its Current Ratio is at 4.71. In the meantime, Its Debt-to-Equity ratio is 0.37 whereas as Long-Term Debt/Eq ratio is at 0.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on October 07, 2025, initiated with a Overweight rating and assigned the stock a target price of $40.
On October 08, 2024, Redburn Atlantic started tracking the stock assigning a Buy rating and target price of $86.
On June 17, 2024, Truist started tracking the stock assigning a Buy rating and target price of $88.Truist initiated its Buy rating on June 17, 2024, with a $88 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 26 ’25 when Casey Patrick John bought 1,000 shares for $33.28 per share.
Huang Ying bought 1,370 shares of LEGN for $45,210 on Sep 24 ’25. On Sep 23 ’25, another insider, Huang Ying, who serves as the Officer of the company, bought 1,357 shares for $33.98 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LEGN now has a Market Capitalization of 6223724544 and an Enterprise Value of 11686926336. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.81 while its Price-to-Book (P/B) ratio in mrq is 6.01. Its current Enterprise Value per Revenue stands at 14.667 whereas that against EBITDA is -55.915.
Stock Price History:
The Beta on a monthly basis for LEGN is 0.18, which has changed by -0.22882336 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, LEGN has reached a high of $51.77, while it has fallen to a 52-week low of $27.34. The 50-Day Moving Average of the stock is -2.06%, while the 200-Day Moving Average is calculated to be -3.35%.
Shares Statistics:
According to the various share statistics, LEGN traded on average about 1.26M shares per day over the past 3-months and 1703450 shares per day over the past 10 days. A total of 184.57M shares are outstanding, with a floating share count of 180.77M. Insiders hold about 2.06% of the company’s shares, while institutions hold 44.86% stake in the company. Shares short for LEGN as of 1759190400 were 9351983 with a Short Ratio of 7.43, compared to 1756425600 on 7859738. Therefore, it implies a Short% of Shares Outstanding of 9351983 and a Short% of Float of 9.689999.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 6.0 analysts currently analyzing and rating the stock of Legend Biotech Corp ADR (LEGN).The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.01 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.08 and -$1.46 for the fiscal current year, implying an average EPS of -$0.63. EPS for the following year is $0.49, with 6.0 analysts recommending between $0.89 and $0.29.
Revenue Estimates
According to 12 analysts,. The current quarter’s revenue is expected to be $277.75M. It ranges from a high estimate of $302.63M to a low estimate of $231.4M. As of. The current estimate, Legend Biotech Corp ADR’s year-ago sales were $160.21MFor the next quarter, 12 analysts are estimating revenue of $326.53M. There is a high estimate of $399.06M for the next quarter, whereas the lowest estimate is $280M.
A total of 15 analysts have provided revenue estimates for LEGN’s current fiscal year. The highest revenue estimate was $1.14B, while the lowest revenue estimate was $945.6M, resulting in an average revenue estimate of $1.05B. In the same quarter a year ago, actual revenue was $627.24MBased on 15 analysts’ estimates, the company’s revenue will be $1.55B in the next fiscal year. The high estimate is $1.72B and the low estimate is $1.45B.
